Ancillary study evaluating ChAd155-hIi-HBV shedding in a subset of chronic hepatitis B patients enrolled in the first-time-in-human, Phase I/II, randomised, multi-centric, single-blind study TH HBV VV-001
Latest Information Update: 05 Sep 2023
At a glance
- Drugs ChAd155 hIi HBV (Primary) ; HBc HBs/AS01B 4 (Primary) ; MVA HBV (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms TH HBV VV-031 HBS:001
- Sponsors GlaxoSmithKline Biologicals; GSK
Most Recent Events
- 21 Mar 2022 New trial record